Specifically, we assessed the CEA TCB Cibisatamab, a 2:1 bispecific antibody targeting CEA on tumor cells and CD3ε on T cells, using cancer spheroids and healthy organoids [23]. Here, CEACAM5 is linked to neoplasm.